tonlamarsen (ION904) / Ionis, Kardigan - LARVOL DELTA

A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL) (clinicaltrials.gov) - P2 | N=206 | Active, not recruiting | Sponsor: Kardigan, Inc. | N=700 ➔ 206 | Trial completion date: Dec 2027 ➔ Mar 2026 | Trial primary completion date: Feb 2027 ➔ Jan 2026

Enrollment change • Trial completion date • Trial primary completion date • Cardiovascular • Hypertension

A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (clinicaltrials.gov) - P2 | N=700 | Active, not recruiting | Sponsor: Kardigan, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Hypertension

A Study to Investigate Tonlamarsen for the Treatment of Adults with Uncontrolled Hypertension (clinicaltrials.gov) - P2 | N=700 | Recruiting | Sponsor: Kardigan, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Hypertension

Effect of ION904, an Antisense Inhibitor of Angiotensinogen Production: Results of Phase 1 and Phase 2 Pilot Studies (AHA 2023) - "We previously published that inhibiting angiotensinogen (AGT) mRNA in hepatocytes with GalNAc-modified antisense oligonucleotide (ASO)-IONIS-AGT-LRx given subcutaneously (SC) weekly is effective in significantly reducing plasma angiotensinogen (AGT) with no on-target or off-target effects. Monthly administration of ION904 demonstrated significant plasma AGT reductions with a favorable safety and tolerability profile supporting development in heart failure and hypertension."

Clinical • P1 data • P2 data • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders • Hepatology • Hypertension • Hypotension • Liver Failure • Nephrology • Renal Disease • Thrombocytopenia

A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled Hypertension (clinicaltrials.gov) - P2 | N=48 | Completed | Sponsor: Ionis Pharmaceuticals, Inc. | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Hypertension

A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled Hypertension (clinicaltrials.gov) - P2 | N=48 | Active, not recruiting | Sponsor: Ionis Pharmaceuticals, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Hypertension

A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled Hypertension (clinicaltrials.gov) - P2 | N=48 | Recruiting | Sponsor: Ionis Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Hypertension

A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled Hypertension (clinicaltrials.gov) - P2 | N=48 | Not yet recruiting | Sponsor: Ionis Pharmaceuticals, Inc.

New P2 trial • Hypertension

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION904 (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Ionis Pharmaceuticals, Inc. | Active, not recruiting ➔ Completed

Trial completion

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION904 (clinicaltrials.gov) - P1; N=40; Active, not recruiting; Sponsor: Ionis Pharmaceuticals, Inc.; Recruiting ➔ Active, not recruiting; N=72 ➔ 40

Clinical • Enrollment change • Enrollment closed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION904 (clinicaltrials.gov) - P1; N=72; Recruiting; Sponsor: Ionis Pharmaceuticals, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open